Does Lenacapavir Sodium Interact with Sensitive Cyp3a Substrates?
Lenacapavir Sodium and Sensitive Cyp3a Substrates have a moderate drug interaction according to U.S. FDA drug labeling data. YEZTUGO may increase concentrations of sensitive CYP3A substrates, resulting in increased risk of adverse events. Monitoring or dosing adjustments may be needed. The mechanism involves moderate cyp3a inhibition by lenacapavir. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This information is based on official FDA drug labeling sourced from OpenFDA and the NIH National Library of Medicine.
- Severity
- Moderate
- Management
- Monitor for effects
- Data Source
- U.S. FDA via OpenFDA
How This Interaction Works
The interaction between Lenacapavir Sodium and Sensitive Cyp3a Substrates occurs because moderate cyp3a inhibition by lenacapavir. Clinically, this means yeztugo may increase concentrations of sensitive cyp3a substrates, resulting in increased risk of adverse events. monitoring or dosing adjustments may be needed. This is classified as a moderate interaction. While it may not require stopping either medication, your healthcare provider should be aware you are taking both so they can monitor for potential effects and adjust treatment if necessary.
What To Tell Your Doctor or Pharmacist
If you are taking Lenacapavir Sodium and your doctor is considering prescribing Sensitive Cyp3a Substrates (or vice versa), make sure to:
- Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
- Ask whether the benefits of combining these medications outweigh the risks for your specific situation
- Ask what symptoms to watch for that would indicate the interaction is causing problems
- Ask whether any dosage adjustments are needed
- Never stop or change either medication without first consulting your healthcare provider